Non-GLP Toxicity Assessment Services

カスタムモデルジェネレーションサービス
前臨床試験サービス
Bioanalytical ServicesPhenotyping ServicesAnti-Tumor Drug Efficacy EvaluationNon-GLP Toxicity Assessment ServicesMetabolic Disease Efficacy EvaluationAutoimmune Disease Efficacy EvaluationNeurodegenerative Disease Efficacy EvaluationCell Therapy & Gene Therapy Efficacy Evaluation
菌および微生物叢サービス
Mouse-Derived Gut Microbiota LibraryMicrobial Strain Culture and ColonizationGerm-free Rederivation and BreedingMicrobiota Extraction and TransplantationEvaluation of Anti-tumor Effect of Gut MicrobiotaCustomized Germ-free Services
細胞株とカスタマイゼーションサービス
Cell Line Customization ServicesCDX Cell LinesReporter Cell LinesSyngeneic Cell Lines
カスタムブリーディングサービス
Customized Mice Breeding ServicesCryopreservation and ResuscitationAssisted ReproductionMouse Rederivation Service
実験動物の品質試験サービス
SNP Testing ServicesMicrobiology Testing ServicesGenetic IntegrityAnimal HealthAnimal Welfare
その他のサービス
Animal Facility and HusbandryReproductive and Embryology Services Isolation of Embryonic Fibroblasts

Because BALB/c mice are more susceptible to immune-related adverse events (irAEs), GemPharmatech provides immune-checkpoint inhibitor-related toxicity evaluations. The irAEs of immune-checkpoint inhibitors can be evaluated by clinical observation of mice, pathological evaluation, testing of cytokines, and monitoring of clinical indexes dynamically during the dosing process, all of which provides an effective toxicity evaluation platform for preclinical research of ICIs.


BALB/c-hCTLA4 Models

The toxic side effects of anti-PD1 + anti-CTLA4 combination therapy were evaluated with C57BL/6-hPD1/hCTLA4 and BALB/c-hPD1/hCTLA4 mice, respectively.

1. The survival curve of the PD1 antibody + Yervoy combo therapy in B6 and BALB/c mice showed that BALB/c mice died on Day 9 and were not tolerant until Day 18 in the study.

1.png


2. Clinical trial data for the CTLA4-targeting drug Yervoy showed that patients suffered severe side effects, including dermatitis, hepatitis, diarrhea, and rectocolitis. BALB/c mice exhibited pathological symptoms such as arthritis, rashes, and depilation, but B6 mice exhibited no such symptoms.

2.png

3.png


3. During the clinical biochemical assessment of Yervoy, the levels of lactate dehydrogenase (LDH) and creatine kinase (CK) were significantly higher in BALB/c mice than in B6 mice, indicating that the cardiac damage produced by Yervoy was more severe in BALB/c animals.

4.png


4. Yervoy caused inflammatory injury on mice hearts to varied severity. Inflammatory lesions observed in BALB/c murine hearts were more severe than in B6 background mice. 

5.png


B6-hPD1/CTLA4 mouse models proved tolerant to drug therapies; humanized immune checkpoint BALB/c-hPD1/hPD1 mice make ideal models for evaluating macromolecular and small-molecule drug toxicity in preclinical trials due to their ability to reproduce certain adverse reactions (ARs) in clinical practice.

TALK WITH OUR EXPERTS

GemPharmatechは、お客様のプライバシーを保護し、尊重することをお約束します。お客様の個人情報は、アカウントの管理およびお客様からご要望いただいた製品やサービスの提供に利用いたします。時折、当社の製品やサービスに関する情報や、お客様に興味があるかもしれない他のコンテンツについてご連絡差し上げたいと考えております。お客様にこの目的をご連絡し、ご同意いただける場合は、以下の方法でお客様にどのようにご連絡させていただけるかをお知らせください。

ご希望のコンテンツを提供するために、お客様の個人データを保存および処理する必要があります。この目的でお客様の個人データを保存することにご同意いただける場合は、以下のチェックボックスをクリックしてください。

同意をいつでも撤回する権利があります。購読解除の詳細情報、当社のプライバシーに関する実践、およびお客様のプライバシーを保護し尊重するための取り組みについての詳細については、当社のプライバシーポリシーをご覧ください。